Here are four approvals, changes and recalls made by the FDA that are connected to the anesthesia space, as reported by Becker’s so far in 2025.
- The FDA has announced requirements for safety labeling on all opioid pain medications that place renewed emphasis on the risks associated with their long-term use.
- The FDA issued a Class I recall for multiple anesthesia breathing circuit kits due to cracks in the hose that could cause inadequate ventilation.
- Pharmaceutical company Avenacy launched Propofol injectable emulsion, USP, in the U.S. to be used for intravenous general anesthetic and sedation. The drug is approved by the FDA as a generic equivalent to general anesthetic Diprivan.
- Specialty pharmaceutical company PharmaTher Holdings’ drug application for Ketamine was advanced by the FDA.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.